9413 Phase II trial of adjuvant imatinib mesylate after resection of localized, primary high risk gastrointestinal stromal tumour (GIST) in Japan

Stromal Tumour ◽

Adjuvant Imatinib

Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.9009 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 9009-9009 ◽

Cited By ~ 21

Author(s):

R. P. Dematteo ◽

C. R. Antonescu ◽

V. Chadaram ◽

Y. N. You ◽

L. McCall ◽

...

Keyword(s):

High Risk ◽

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Complete Resection ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

The U.S

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

Yearbook of Gastroenterology ◽

10.1016/s0739-5930(09)79325-0 ◽

2009 ◽

Vol 2009 ◽

pp. 150-151 ◽

Cited By ~ 1

Author(s):

D.T. Dempsey

Keyword(s):

Imatinib Mesylate ◽

Controlled Trial ◽

Stromal Tumour ◽

Adjuvant Imatinib ◽

Double Blind ◽

Double Blind Placebo

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-018-0169-9 ◽

2019 ◽

Vol 17 (1) ◽

Cited By ~ 1

Author(s):

Thanaporn Bussabawalai ◽

Kittiphong Thiboonboon ◽

Yot Teerawattananon

Keyword(s):

High Risk ◽

Cost Utility ◽

Cost Utility Analysis ◽

Stromal Tumour ◽

Imatinib Treatment ◽

Adjuvant Imatinib ◽

Utility Analysis ◽

Risk Of Recurrence

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

Journal of Surgical Oncology ◽

10.1002/jso.21160 ◽

2009 ◽

Vol 99 (1) ◽

pp. 42-47 ◽

Cited By ~ 247

Author(s):

Burton L. Eisenberg ◽

Jonathan Harris ◽

Charles D. Blanke ◽

George D. Demetri ◽

Michael C. Heinrich ◽

...

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Early Results

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(09)60500-6 ◽

2009 ◽

Vol 373 (9669) ◽

pp. 1097-1104 ◽

Cited By ~ 871

Author(s):

Ronald P DeMatteo ◽

Karla V Ballman ◽

Cristina R Antonescu ◽

Robert G Maki ◽

Peter WT Pisters ◽

...

Keyword(s):

Imatinib Mesylate ◽

Controlled Trial ◽

Stromal Tumour ◽

Adjuvant Imatinib ◽

Double Blind ◽

Double Blind Placebo

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 ‘CaboGIST’

European Journal of Cancer ◽

10.1016/j.ejca.2020.04.021 ◽

2020 ◽

Vol 134 ◽

pp. 62-74 ◽

Cited By ~ 5

Author(s):

Patrick Schöffski ◽

Olivier Mir ◽

Bernd Kasper ◽

Zsuzsanna Papai ◽

Jean-Yves Blay ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Phase Ii ◽

Kinase Inhibitor ◽

Phase Ii Trial ◽

Stromal Tumour ◽

European Organisation

Faculty Opinions recommendation of Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1157706.617831 ◽

2009 ◽

Author(s):

Florence Duffaud

Keyword(s):

Imatinib Mesylate ◽

Controlled Trial ◽

Stromal Tumour ◽

Adjuvant Imatinib ◽

Double Blind ◽

Double Blind Placebo

Faculty Opinions recommendation of Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1147293.604446 ◽

2009 ◽

Author(s):

Florence Duffaud

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Early Results

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.10057 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 10057-10057 ◽

Cited By ~ 1

Author(s):

D. Wang ◽

Q. Zhang ◽

C. D. Blanke ◽

G. D. Demetri ◽

M. C. Heinrich ◽

...

Keyword(s):

Imatinib Mesylate ◽

Phase Ii ◽

Phase Ii Trial ◽

Stromal Tumor ◽

Adjuvant Imatinib ◽

Long Term Follow Up

Faculty Opinions recommendation of HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718151420.793488671 ◽

2013 ◽

Author(s):

Brian Keith Bednarski

Keyword(s):

Rectal Cancer ◽

High Risk ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii